What is HC Wainwright’s Forecast for RAPP FY2027 Earnings?

by · The Cerbat Gem

Rapport Therapeutics, Inc. (NASDAQ:RAPP – Free Report) – Research analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for Rapport Therapeutics in a note issued to investors on Tuesday, December 9th. HC Wainwright analyst D. Tsao now expects that the company will earn ($3.65) per share for the year, up from their prior estimate of ($3.80). HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ FY2028 earnings at ($4.76) EPS and FY2029 earnings at ($3.83) EPS.

RAPP has been the subject of several other research reports. BTIG Research restated a “buy” rating and set a $47.00 target price on shares of Rapport Therapeutics in a research report on Monday. Truist Financial began coverage on shares of Rapport Therapeutics in a research report on Tuesday, September 16th. They set a “buy” rating and a $44.00 target price for the company. Wall Street Zen lowered shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. The Goldman Sachs Group raised shares of Rapport Therapeutics to a “strong-buy” rating in a research note on Friday, September 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $47.80.

View Our Latest Research Report on Rapport Therapeutics

Rapport Therapeutics Stock Up 0.1%

NASDAQ:RAPP opened at $28.67 on Thursday. The firm has a 50-day moving average price of $26.98 and a 200 day moving average price of $19.87. The firm has a market capitalization of $1.37 billion, a PE ratio of -10.58 and a beta of 1.63. Rapport Therapeutics has a 12-month low of $6.43 and a 12-month high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.06.

Hedge Funds Weigh In On Rapport Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Capital International Investors raised its stake in Rapport Therapeutics by 30.7% during the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after buying an additional 800,000 shares during the period. Vanguard Group Inc. increased its holdings in shares of Rapport Therapeutics by 46.9% in the third quarter. Vanguard Group Inc. now owns 1,626,538 shares of the company’s stock worth $48,308,000 after acquiring an additional 519,047 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in shares of Rapport Therapeutics by 181.2% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock valued at $45,949,000 after purchasing an additional 997,000 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Rapport Therapeutics by 4.1% during the 2nd quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company’s stock valued at $13,129,000 after purchasing an additional 45,063 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new position in shares of Rapport Therapeutics in the 3rd quarter valued at approximately $28,215,000.

Insider Buying and Selling

In other news, CEO Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock in a transaction on Monday, November 17th. The stock was sold at an average price of $25.20, for a total value of $128,091.60. Following the completion of the sale, the chief executive officer directly owned 35,978 shares of the company’s stock, valued at approximately $906,645.60. This trade represents a 12.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $25.19, for a total value of $214,115.00. Following the completion of the sale, the insider owned 401,142 shares of the company’s stock, valued at approximately $10,104,766.98. The trade was a 2.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 115,252 shares of company stock valued at $3,001,471. 13.57% of the stock is currently owned by company insiders.

Rapport Therapeutics Company Profile

(Get Free Report)

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.

Featured Stories